Stay updated with breaking news from Virtual Plenary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – –...
Longer-term results from the OlympiA trial show a 32% improvement in overall survival with olaparib among women with early-stage germline BRCA-mutated breast cancer.
NEWTON, Mass. - Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that results from the Phase 3 SIENDO study will be presented at... | March 17, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...